{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:12:16Z","timestamp":1783152736712,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS109762"],"award-info":[{"award-number":["R21NS109762"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R25GM064120"],"award-info":[{"award-number":["R25GM064120"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["T32 GM008396"],"award-info":[{"award-number":["T32 GM008396"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.omtm.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:05:25Z","timestamp":1628399125000},"page":"23-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB\/NJ-Ighmpb2"],"prefix":"10.1016","volume":"23","author":[{"given":"Monir","family":"Shababi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caley E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Ricardez Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Al Rawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Villal\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. David","family":"Farris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona O.","family":"Garro-Kacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Lorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.07.008_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng703","article-title":"Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1","volume":"29","author":"Grohmann","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2021.07.008_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ana.10755","article-title":"Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"54","author":"Grohmann","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2021.07.008_bib3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/302636","article-title":"Diaphragmatic spinal muscular atrophy with respiratory distress is heterogeneous, and one form Is linked to chromosome 11q13-q21","volume":"65","author":"Grohmann","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2021.07.008_bib4","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1093\/brain\/awg278","article-title":"Severe infantile neuropathy with diaphragmatic weakness and its relationship to SMARD1","volume":"126","author":"Pitt","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2021.07.008_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3758\/BF03196467","article-title":"Flexibility versus generalizability in model selection","volume":"10","author":"Pitt","year":"2003","journal-title":"Psychon. Bull. Rev."},{"key":"10.1016\/j.omtm.2021.07.008_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0883073807310989","article-title":"Spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"23","author":"Kaindl","year":"2008","journal-title":"J.\u00a0Child. Neurol."},{"key":"10.1016\/j.omtm.2021.07.008_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2004-820994","article-title":"Long-term observations of patients with infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"35","author":"Rudnik-Sch\u00f6neborn","year":"2004","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.omtm.2021.07.008_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.10182","article-title":"Mapping of autosomal recessive chronic distal spinal muscular atrophy to chromosome 11q13","volume":"51","author":"Viollet","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2021.07.008_bib9","doi-asserted-by":"crossref","first-page":"17463","DOI":"10.1016\/S0021-9258(19)85357-7","article-title":"The human S mu bp-2, a DNA-binding protein specific to the single-stranded guanine-rich sequence related to the immunoglobulin mu chain switch region","volume":"268","author":"Fukita","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2021.07.008_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/humu.9241","article-title":"Allelic heterogeneity of SMARD1 at the IGHMBP2 locus","volume":"23","author":"Maystadt","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2021.07.008_bib11","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1093\/nar\/gks792","article-title":"The Ighmbp2 helicase structure reveals the molecular basis for disease-causing mutations in DMSA1","volume":"40","author":"Lim","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2021.07.008_bib12","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1073\/pnas.94.15.7831","article-title":"Association of the mammalian helicase MAH with the pre-mRNA splicing complex","volume":"94","author":"Molnar","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.07.008_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-1119(96)00630-0","article-title":"Evidence for regulation of transcription and replication of the human neurotropic virus JCV genome by the human S(mu)bp-2 protein in glial cells","volume":"185","author":"Chen","year":"1997","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2021.07.008_bib14","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1046\/j.1432-1327.2000.01836.x","article-title":"The rat ortholog of the presumptive flounder antifreeze enhancer-binding protein is a helicase domain-containing protein","volume":"267","author":"Miao","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.omtm.2021.07.008_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/viro.1998.9588","article-title":"Smubp-2 represses the Epstein-Barr virus lytic switch promoter","volume":"255","author":"Zhang","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2021.07.008_bib16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/hmg\/ddp134","article-title":"Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery","volume":"18","author":"de Planell-Saguer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.07.008_bib17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/hmg\/ddp028","article-title":"IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1)","volume":"18","author":"Guenther","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.07.008_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00293010","article-title":"Neuromuscular degeneration (nmd): a mutation on mouse chromosome 19 that causes motor neuron degeneration","volume":"6","author":"Cook","year":"1995","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.omtm.2021.07.008_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0896-6273(00)80652-2","article-title":"Identification of the mouse neuromuscular degeneration gene and mapping of a second site suppressor allele","volume":"21","author":"Cox","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2021.07.008_bib20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/hmg\/ddh222","article-title":"Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"13","author":"Grohmann","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.07.008_bib21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/mt.2016.33","article-title":"Rescue of a Mouse Model of Spinal Muscular Atrophy With Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent","volume":"24","author":"Shababi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.07.008_bib22","doi-asserted-by":"crossref","first-page":"e1500078","DOI":"10.1126\/sciadv.1500078","article-title":"Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model","volume":"1","author":"Nizzardo","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2021.07.008_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.omtm.2018.08.005","article-title":"A Direct Comparison of IV and ICV Delivery Methods for Gene Replacement Therapy in a Mouse Model of SMARD1","volume":"10","author":"Shababi","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.07.008_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2019.10.032","article-title":"Development of a novel severe mouse model of spinal muscular atrophy with respiratory distress type 1: FVB-nmd","volume":"520","author":"Shababi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtm.2021.07.008_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2021.07.008_bib26","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","article-title":"Defining the therapeutic window in a severe animal model of spinal muscular atrophy","volume":"23","author":"Robbins","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.07.008_bib27","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI57291","article-title":"Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy","volume":"121","author":"Lutz","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2021.07.008_bib28","doi-asserted-by":"crossref","first-page":"e3468","DOI":"10.1371\/journal.pone.0003468","article-title":"Development of a single vector system that enhances trans-splicing of SMN2 transcripts","volume":"3","author":"Coady","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.07.008_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12031-011-9614-3","article-title":"Optimization of SMN Trans-Splicing Through the Analysis of SMN Introns","volume":"46","author":"Shababi","year":"2012","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.omtm.2021.07.008_bib30","doi-asserted-by":"crossref","first-page":"e89970","DOI":"10.1172\/jci.insight.89970","article-title":"Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy","volume":"2","author":"Kaifer","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2021.07.008_bib31","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/hmg\/ddt037","article-title":"Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy","volume":"22","author":"Cobb","year":"2013","journal-title":"Hum. Mol. Genet."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012100125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012100125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:30:03Z","timestamp":1762421403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012100125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"alternative-id":["S232905012100125X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.07.008","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB\/NJ-Ighmpb2 nmd-2J","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}